18 September 2023
18 September 2023
Commercial clinical trial initiation has decreased over the past five years in the UK however, Greater Manchester has bucked the trend.
The CAR-T cell therapy was approved for treating relapsed/refractory large B-cell lymphoma in 2022.
Lipocine plans to initiate two registrational trials with LPCN 1148 in cirrhosis and LPCN 1154 in postpartum depression.
Non-invasive neuromodulation therapy could provide an alternative option to pharmaceutical treatment for the neurodegenerative disease.
Experts say a wider diverse pool of patients needs to be given a chance to participate in clinical research to get rare disease drugs faster to market.
While orphan drug approvals have hit an all-time high, existing incentives need to continue to further support rare disease research.
A new report found that the Remote Patient Monitoring (RPM) sector will grow, since the pandemic revealed the benefits of remote healthcare.
The Excellence Awards celebrate the greatest achievements and innovations in the industry, and the people and companies that are driving change.
The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy classes combined. The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, there are also multiple allogeneic CAR-Ts in the pipeline, with these therapies having an “off-the-shelf” advantage over autologous therapies.
Give your business an edge with our leading industry insights.
